Skip to main
ZURA

ZURA Stock Forecast & Price Target

ZURA Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Zura Bio is viewed favorably because its lead asset, tibulizumab, offers a differentiated BAFF x IL-17A mechanism that could break the efficacy ceiling in hidradenitis suppurativa while also showing orthogonal potential in polymyalgia rheumatica and systemic sclerosis. The near-term catalyst-rich setup is compelling, with TibuSHIELD enrollment of 247 versus a 225 target, results expected in late Oct./early Nov., and SSc readout in 1H27, all supported by $205.1MM in 2Q26 cash and a runway through at least YE28. The added PMR program, a planned Phase 2 start by year-end 2026, and modeled 2035E worldwide sales of $1.6B for tibulizumab reinforce a multi-indication growth story with meaningful upside from an underpenetrated autoimmune market.

Bears say

Zura Bio is a high-risk clinical-stage biotechnology company whose outlook is weighed down by the possibility that tibulizumab and the broader pipeline may fail to demonstrate sufficient efficacy or safety in target indications. Clinical or regulatory setbacks could halt development entirely, while an inability to achieve sales estimates would undermine the commercial case for its lead programs. Even if development progresses, tibulizumab faces competitive pressure from current and future therapies, and manufacturing or shipment disruptions could further impair execution.

ZURA has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zura Bio Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zura Bio Ltd (ZURA) Forecast

Analysts have given ZURA a Strong Buy based on their latest research and market trends.

According to 5 analysts, ZURA has a Strong Buy consensus rating as of Oct 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zura Bio Ltd (ZURA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.